Interní Med. 2015; 17(5): 227-229

Not only diseases of the pancreas and their therapy with pancreatic enzymes

prof.MUDr.Petr Dítě, DrSc.1, MUDr.Martina Bojková1, Mgr.Jarmila Šímová2, MUDr.Bohuslav Kianička, Ph.D.3, MUDr.Kateřina Kapounková4, MUDr.Vladimír Hrabovský, Ph.D.4
1 Akademické centrum gastroenterologie, Interní klinika FN a LF Ostrava
2 CGB Laboratoř, Výzkumný institut Agel, Ostrava
3 II. interní klinika &ndash, Gastroenterologické oddělení FN u sv. Anny, LF MU Brno
4 Katedra podpory zdraví, Fakulta sportovních studií MU Brno

Exocrine pancreatic insufficiency is a serious condition clinically manifested by signs of pancreatic malnutrition. The treatment of these

conditions is based on administration of drugs containing pancreatic enzymes of which lipase has the crucial role in the process of

digestion. Pancreatic enzymes are delivered in the form of capsules that contain microparticles containing pancreatic enzymes – amylase,

lipase, and peptidases. The microparticles are protected from possibly being inactivated by gastric hydrochloric acid by a pH-sensitive

coating that is disintegrated only at a pH of 5.0–6.0. This ensures the release of enzymes from the microparticles at the time when chyme

along with the microparticles enter the upper part of the duodenum.

The most common indication for treatment with pancreatic supplementation is chronic pancreatitis; in addition, large amounts of lipase

are administered in persons with abdominal-type cystic fibrosis, in pancreatic tumours as well as in celiac disease, diabetes mellitus, or

post-gastrectomy states.

In order for the treatment to be successful, it is necessary to administer sufficient quantities of enzymes, i.e. with each main meal 40,000–50,000

U of lipase; with other smaller meals 10,000–25,000 U of lipase, i.e. a capsule containing pancreatic enzymes is given during each meal.

The effect of treatment can be estimated by clinical data, i.e. a change in the nature and number of stools, change in body weight, or by

using a fat absorption test.

Keywords: exocrine pancreatic insufficiency, pancreatic enzymes, amylase, lipase, peptidases

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dítě P, Bojková M, Šímová J, Kianička B, Kapounková K, Hrabovský V. Not only diseases of the pancreas and their therapy with pancreatic enzymes. Interní Med. 2015;17(5):227-229.
Download citation

References

  1. Mohr A, Drewes A. Diagnosis and treatment of exocrine pancreatic insufficiency. WJG 2013; 19: 7258-7266. Go to original source... Go to PubMed...
  2. Sickens EC, Cahen DL, Koch AD, et al. The prevalence of fat-soluble vitamin deficiences and decrease of bone mass in patients with chronic pancreatitis. Pancreatology 2013; 13: 238-242. Go to original source... Go to PubMed...
  3. Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. WJG 2013; 19: 7258-7266. Go to original source... Go to PubMed...
  4. Trang T, Chan J, Graham D Y. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in th 21st century. WJG, 2014; 7, 20(33): 11467-11483. Go to original source... Go to PubMed...
  5. Keller J, Bruckel S, Jahr C, et al. A modified 13C-breath test detects moderate pancreatic insufficiency. Pancreas 2011; 40: 1201-1205. Go to original source... Go to PubMed...
  6. Hart PA, Conwell DE. Diagnosis of exocrine pancreatic insufficiency. Cuur. Treat Options Gastro 2015; 13: 347-353. Go to original source... Go to PubMed...
  7. Berry AM. Pancreatic enzymy replacement therapy during pancreatic insufficiency. Nutrition in Clinical Practice. 2014; 29(3): 312-321. Go to original source... Go to PubMed...
  8. Meyer JH, Elshoff J, Porter-Fink V, et al. Human postprandial gastric emptying of 1-3 millimeter spheres. Gastroenterology 1988; 94: 1315-1325. Go to original source... Go to PubMed...
  9. Thorat V, Reddy N, Bhatia S, et al. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres'Creon 40 000 MMS) in patients with pancreatic exocrine insufficiency due the chronic pancreatitis - a double blind,placebo controlled study. Aliment Pharm Therapy 2012; 36: 426-436. Go to original source... Go to PubMed...
  10. Pezzilli R, Andriulli A, Bassi C, et al. Exocrine pancreatic insufficiency in adlults : A sharp position statement of the Italian association for the study of the pancreas. WJG 2013; 19: 7930-7946. Go to original source... Go to PubMed...
  11. Graham DY. Pancreatic enzyme replacement: the effect of antacids or cimetidine. Dig Dis Sci 1982; 94: 485-490. Go to original source... Go to PubMed...
  12. Bruno MJ, Rauws EA, Hock FJ, et al. Comparative effect of adjuvant of cimetidine and omeprazole during pancreatic enzyme replacement therapy. Dig Dis Sci 1994; 39: 988-992. Go to original source... Go to PubMed...
  13. Fitz-simmons SC, Buerkhardt GA, Borowitz D, et al. High-dose of pancreatic enzyme supplements and fibrozing colonopathy in children with cystic fibrosis. N Engl J Med 1997; 336: 1283-1289. Go to original source... Go to PubMed...
  14. Dominguez-Munoz JE, Iglesias-Garcia S. Oral pancreatic enzyme substitution therapy in chronic pancreatitis.: is clinical response an appropriate marker for evaluation of therapeutic efficacy JOP 2010; 11: 158-162. Go to PubMed...
  15. Sadr-Azodi O, Sanders DS, Murray JA, et al. Patients with celiac disease have an increased risk for pancreatitis. Clin Gastroenterol Heatol. 2012; 10: 1136-1142. Go to original source... Go to PubMed...
  16. Maconi G, Dominici R, Molteni M. Prevalence of pancreatic insufficiency in inflammatory bowel disease. Assessment by fat elastase 1. Dig Dis Sci 2008; 53: 262-270. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.